SAA1 and fatty liver disease: SAA1 can increase hepatic steatosis, activate HSCs, and increase ECM deposition in the liver via the Toll-like receptor (TLR) pathways, and its levels are increased in the liver and blood of patients with MASLD [11,19–21].